Comparative Pharmacology
Head-to-head clinical analysis: BRISDELLE versus FLUOXETINE POSTPARTUM SAFETY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISDELLE versus FLUOXETINE POSTPARTUM SAFETY.
BRISDELLE vs Fluoxetine-Safety-Postpartum
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
8 mg orally once daily, taken at bedtime.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
None Documented
None Documented
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Category C
Category A/B
SSRI Antidepressant
SSRI Antidepressant